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Accepted 20 January 2020; Published online 23 January 2020AbstractObjectives: The aim of this study was to reanalyze and reinterpret data obtained in Paracetamol in Acute Low Back Pain (PACE), the
first large randomized controlled trial evaluating the efficacy of paracetamol in acute low back pain, to assess the inferential reproducibility
of the original conclusions.
Study Design and Setting: Mixed effects models were used to reanalyze pain intensity (primary outcome; 11-point Numeric Rating
Scale) and physical functioning, health-related quality of life, sleep quality, and time until recovery (as secondary outcomes), according to
the intention-to-treat principle. The original authors of the PACE study were not involved in the development of the methods for this
reanalysis.
Results: The reproduction analyses indicated no effect of treatment on pain intensity and confidence intervals excluded clinically
worthwhile effects (adjusted main effect for regular paracetamol vs. placebo 0.00 [0.02, 0.01; P 5 0.85]; adjusted main effect for para-
cetamol as-needed vs. placebo 0.00 [0.02, 0.01; P 5 0.92]). Similar results were obtained for all secondary outcomes.
Conclusion: This study indicates that the conclusions of the PACE trial are inferentially reproducible, even when using a different
analytical approach. This reinforces the notion that the management of acute low back pain should focus on providing patients advice
and reassurance without the addition of paracetamol.  2020 The Authors. Published by Elsevier Inc. This is an open access article under
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Key findings
 This inferential reproduction study showed that
paracetamol was not more effective than placebo
on core outcomes of low back pain, confirming
the original results of Paracetamol in Acute Low
Back Pain (PACE), the first randomized controlled
trial investigating the efficacy of paracetamol for
acute low back pain.
What this adds to what was known?
 The present study is the first independent inferen-
tial reproduction analysis in the field of low back
pain research. Although a different statistical
approach was used, our analyses unequivocally
confirm the conclusions from the PACE trial.
 As the PACE trial remains the first and only trial
showing that paracetamol had no effect on the out-
comes of acute low back pain and has, therefore,
been highly influential on clinical practice guide-
lines, the reproducibility of its results is of vital
importance.
What is the implication and what should change
now?
 The outcome of this study is highly relevant
because several national clinical practice guide-
lines still recommend paracetamol as first-choice
analgesic for acute low back pain.
 The available evidence suggests that the manage-
ment of acute low back pain should focus on
providing patients advice and reassurance without
the addition of paracetamol.1. Introduction
Paracetamol (acetaminophen) used to be the first-choice
analgesic for acute low back pain (LBP), but several recent
clinical practice guidelines have abandoned this recommen-
dation because of new evidence about its lack of efficacy
[2e6]. This evidence came from a 2016 Cochrane Review,
which mainly based its results on the Paracetamol for Acute
Low Back Pain (PACE) trial, the first large placebo-
controlled randomized controlled trial (RCT) concerning
the efficacy of paracetamol in acute LBP [7,8]. As this trial
was highly influential on recent guidelines, the reproduc-
ibility of its results is of great importance [9].
Although the importance of reproducibility of scientific
results is universally agreed upon, the terminology
describing different types of reproducibility is not. In
2016, Goodman et al introduced their ‘‘new lexicon forresearch reproducibility,’’ in which they described three
types of reproducibility: methods reproducibility, results
reproducibility, and inferential reproducibility [10,11].
Methods reproducibility refers to the reproduction of an
analysis using the same data, analysis plan, and code, with
the only difference being the analyst [12,13]. In results
reproduction (also called ‘‘replication’’), new data are
collected in the same population and consequently analyzed
using the same analysis plan [12,13]. Finally, inferential
reproducibility is the making of knowledge claims of
similar strength from either a study replication or reanalysis
of original data [10]. In clinical research, reproduction
studies are often the exception rather than the rule. Howev-
er, early acceptance of scientific claims that are subse-
quently not reproducible may lead to harms or even to
unwarranted ‘‘medical reversal’’ [14]; furthermore, repro-
duction is important in case only little evidence exists about
a certain topic [15].
In the PACE trial, methods reproducibility was already
addressed, as ‘‘Two statisticians who were masked to allo-
cation independently did statistical analyses.’’ [8].
Another RCT evaluating the result of the PACE trial (called
the PACE Plus trial) was discontinued in 2017 because of
insufficient recruitment of participants [16,17]. The pri-
mary outcome in the PACE trial was time until recovery
from LBP, but this outcome is not among the outcome do-
mains most relevant to patients with LBP [18]. A core
outcome set for LBP, published after the PACE trial had
already been completed, including pain intensity, physical
functioning, health-related quality of life (HRQoL), and
number of deaths as core outcome domains [19]. The first
three core domains were included in the PACE original
analysis as secondary outcomes, while no patients died dur-
ing trial participation [8]. In the analysis plan of the discon-
tinued PACE Plus trial, pain intensity recorded in the daily
pain diary was the primary outcome [16]. The original anal-
ysis of the PACE trial reported results for pain intensity at
1, 2, 4, and 12 weeks of follow-up and presented only part
of the data from the pain diary (up to 14 days of follow-up)
in the appendix; not all collected diary data were used [8].
The aim of this study was to reanalyze the original data ob-
tained in the PACE trial to assess the inferential reproduc-
ibility of results obtained in PACE.2. Methods
2.1. Participants and data collection in the PACE trial
A brief description of participants and data collection in
the original PACE trial is provided here; for a detailed
description, see the original manuscripts [8,20]. The PACE
trial was a randomized, placebo-controlled clinical trial that
was conducted from November 2009 until March 2013 in
Sydney, Australia. This RCT was conducted in a multi-
center setting with a double-dummy design, which means
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medication (or placebo) to take three times a day as well
as medication (or placebo) to take as needed for pain. The
study protocol, analysis plan, and main results of the PACE
trial have been published [8,20,21]. A total of 1,652 patients
with a new episode of at least moderate-intensity LBP were
randomly allocated to take paracetamol regularly (1,330 mg
of modified-release paracetamol three times a day, n5 550,
which all were analyzed) or as-needed (up to a maximum of
1,000 mg of regular paracetamol four times a day, n 5 549,
of which 546 were analyzed), or to receive placebo (n5 553,
of which 547 were analyzed). Placebo tablets were identical
in appearance to paracetamol tablets but did not contain the
active component. Participants were instructed to use study
medication until they had experienced seven consecutive
days with pain scores of 0 or 1 out of 10 (measured on a nu-
merical rating scale [NRS]), or for a maximum of 4 weeks,
whichever occurred first. During the trial, participants, clini-
cians, and researchers remained blinded to allocation of
treatment.
Pain scores and the number of tablets used were re-
corded by participants into a daily pain and drug diary until
recovery or for a maximum of 12 weeks. At 1, 2, 3, and
12 weeks after randomization, follow-up questionnaires
were collected.2.2. Outcomes used in this reanalysis
For this reanalysis, the predefined and published analysis
plan from the PACE Plus trial was used [16]. The PACE
Plus trial was a randomized, placebo-controlled clinical
trial that aimed to reproduce the results obtained in the
PACE trial; however, this trial was discontinued because
of insufficient patient recruitment [16,17]. As the groups
and outcomes were similar but not identical between PACE
and PACE Plus, we present primary and secondary out-
comes of the current reproduction analysis here. The pri-
mary outcome of the PACE Plus trial was LBP-intensity
measured with an 11-point NRS (score range 0e10; higher
score means more pain) [22]; this outcome was, therefore,
used as the primary outcome for this study. As specified in
the PACE Plus analysis plan, data from the daily pain and
drug diary collected up to 28 days of follow-up were used
for the current analyses rather than data from the follow-up
questionnaires that were collected after 1, 2, 4, and
12 weeks. Secondary outcome measures from the PACE
Plus analysis plan that were also collected in the PACE trial
were as follows:
 Time to recovery assessed with the daily LBP severity
scores. Recovery is defined as the first day of 0 or 1
pain intensity on a 0e10 pain scale, maintained for
seven consecutive days (primary outcome of the
PACE trial).
 Physical functioning measured with the Roland Mor-
ris Disability Questionnaire (RMDQ; score range0e24; higher score indicates poorer functioning)
[23].
 HRQoL measured with the physical and mental
component summary scores of the Short Form 12
(SF-12, range 0e100; higher score indicates better
HRQoL) [24].
 Sleep quality measured with a 4-point Likert scale
derived from the Pittsburgh Sleep Quality Index.
Scores were dichotomized into good sleep quality
(score 1: ‘‘very good’’ and 2: ‘‘fairly good’’) and poor
sleep quality (score 3: ‘‘fairly bad’’ and 4: ‘‘very
bad’’) [25].2.3. Statistical analysis
The researchers who performed the original analysis of
the PACE trial were not involved in the reanalysis of the
data; two coauthors of the original trial (CM and CL)
involved in this study were only allowed to view the results
and to give their comments in a separate box at the end of
the article after the reanalysis and interpretation had
already been completed. The statistical analysis was per-
formed according to the intention-to-treat (ITT) principle.
The software used for the statistical analysis was R version
3.5.3 (R Core Team, 2019 [26]). An overview of differences
between the original analysis and the current inferential
reproduction analysis can be found in Table 1.
2.4. Primary statistical analysis
For clinical effectiveness, the between-group differences
for the primary outcome, LBP intensity, were evaluated us-
ing a repeated measurements analysis with Poisson mixed
effects models with an adequate specification of the fixed
and random effects structures to account for possible
nonlinear effects. The covariance structure was unstruc-
tured. Poisson mixed effects models rather than linear
mixed effects models were used as pain data were found
to be zero-inflated and nonnormally distributed
(Supplementary Figure 1A); Poisson models have been
demonstrated to be more appropriate for the analysis of
zero-inflated ordinal data such as data obtained from the
NRS [27,28]. The GLMMadaptive R package was used to
create the Poisson mixed effects models [29]. Results are
presented as corrected coefficients for treatment with corre-
sponding 95% confidence intervals (CIs) and P values. A
20% extra improvement in pain in participants receiving
paracetamol compared with those receiving placebo was
considered to be the smallest worthwhile effect [30,31].
2.5. Secondary statistical analysis
We used Poisson mixed effect models for physical func-
tioning as data obtained using the RMDQ was found to be
zero-inflated and nonnormally distributed (see distribution
of data in Supplementary Figure 1B), linear mixed effect
Table 1. Differences between the original analysis by Williams et al and the current inferential reproduction analysis for outcomes of PACE
Outcome
Original analysis (Williams et al., Lancet 2014) Inferential reproduction analysis
P/S Method Presented outcome SA P/S Method Presented outcome SA
Time until
recovery
P Cox proportional
hazards model;
recovery time and
status considered
after 12 wk of
follow-up
Hazard ratios for
recovery for overall
comparisons between
groups after 12 wk of
follow-up
No S Cox proportional
hazards model;
recovery time and
status considered
after 28 days of
follow-up
Hazard ratios for
recovery for overall
comparisons
between groups
after 28 days of
follow-up
Yes
Pain intensity S Linear mixed model
on pain data at 1-,
2-, 4-, and 12-wk
follow-up
Mean and SD in each
group at 1-, 2-, 4- and
12-wk follow-up;
results for analysis of
diary data presented
up to 14 days
No P Poisson mixed model
on pain diary data
up to 28 days of
follow-up
Coefficients for
change in log
average pain
intensity for overall
comparisons
between groups
Yes
Physical
functioning
S Linear mixed model Mean and SD in each
group at 1-, 2-, 4-,
and 12-wk follow-up
No S Poisson mixed model Coefficients for
change in log
average physical
functioning for
overall comparisons
between groups
Yes
Sleep quality S Log binomial
regression
Fractions and
percentages of poor
sleep quality in each
group at 1-, 2-, 4-,
and 12-wk follow-up
No S Logistic regression Odds ratios for poor
sleep quality for
overall comparisons
between groups
No
HRQoL S Linear mixed model Mean and SD in each
group at 1-, 2-, 4-,
and 12-wk follow-up
No S Linear mixed model Coefficients for
change in average
HRQoL for overall
comparisons
between groups
No
Global rating of
symptom
change
S Linear mixed model Mean and SD in each
group at 1-, 2-, 4-,
and 12-wk follow-up
No NA - - -
Abbreviations: HRQoL, health-related quality of life; NA, not analyzed (not in PACE Plus trial protocol); P, Primary outcome; PACE, Paracetamol
in Acute Low Back Pain; S, secondary outcome; SA, subgroup analyses for participants with severe pain intensity (defined as NRS  7) or severe
impairment of physical functioning (defined as RMDQ  16) at baseline; SD, standard deviation.
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quality and a Cox proportional hazards model for time until
first recovery from LBP to assess between-group differ-
ences [27,28]; respective R packages used for the analyses
were GLMMadaptive, lme4, Stats, and Survival
[26,29,32,33]. Sensitivity to missing data in the recovery
analysis was investigated by calculating a best-case sce-
nario and a worst-case scenario for recovery from LBP.
In the best-case scenario, we assumed all missing partici-
pants recovered after the first day of follow-up. In the
worst-case scenario, we assumed none of the missing par-
ticipants recovered within 28 days of follow-up.
As specified in the PACE Plus study protocol, explor-
atory subgroup analyses were conducted for participants
with severe LBP intensity (defined as NRS  7) or severe
impairment of physical functioning (defined as
RMDQ  16) at baseline [16]; for these subgroups, esti-
mates were obtained for LBP intensity, physical function,
and time until recovery using Poisson mixed effects models
and Cox proportional hazard analyses, respectively. The re-
sults are presented as corrected coefficients for treatmentwith corresponding 95% CIs and P values. A 20% extra
improvement in pain from baseline in participants receiving
paracetamol compared with those receiving placebo was
considered to be the smallest worthwhile effect [30,31].3. Results
Reproduced baseline characteristics of participants of
the PACE trial can be found in Table 2. Treatment groups
were comparable at the start of the trial.
Results for the ITT analysis of the primary and second-
ary outcomes are presented in Table 3. Comparisons be-
tween regular paracetamol and placebo, paracetamol as-
needed and placebo, and regular paracetamol and paraceta-
mol as-needed are presented. As an example, the coefficient
for regular paracetamol vs. placebo (0.00, 95% CI: 0.02,
0.01) is interpreted as no change in the log average pain in-
tensity for regular paracetamol when compared with pla-
cebo, when all other predictors remain constant.
Pain intensity diary data were available for 1,601 partic-
ipants (538 from the regular paracetamol group, 530 from
Table 2. Patients and episode characteristics
Patient characteristics Regular group (N [ 550) As-needed group (N [ 546) Placebo group (N [ 547)
Age (y) 44.1 (14.8), N 5 550 45.5 (16.5), N 5 546 45.4 (15.9), N 5 546
Women 263/547 (48%) 256/546 (47%) 245/544 (45%)
Private health insurance 275/550 (50%) 240/545 (44%) 248/544 (46%)
Currently employed 424/550 (77%) 403/546 (74%) 389/542 (72%)
Household income per week (per year)
Negative or no income 19/540 (4%) 11/531 (2%) 22/531 (4%)
AUD 1e649 (1e33,799) 133/540 (25%) 167/531 (31%) 168/531 (32%)
AUD 650e1,699 (33,800-88,399) 243/540 (45%) 243/531 (46%) 226/531 (43%)
AUD 1,700e3,999 (88,400-
207,999)
119/540 (22%) 92/531 (17%) 97/531 (18%)
AUD 4,000 (208,000) 26/540 (5%) 18/531 (3%) 18/531 (3%)
Use of drugs for another disorder 201/550 (37%) 227/543 (42%) 202/544 (37%)
Episode characteristics Regular group (N 5 550) As-needed group (N 5 546) Placebo group (N 5 547)
Days since onset of pain 10.1 (10.1), N 5 550 9.8 (10.0), N 5 546 9.7 (9.8), N 5 546
Number of previous episodes 6.3 (13.7), N 5 547 7.2 (14.9), N 5 544 7.2 (16.8), N 5 544
Presence of pain extending beyond the
knee
108/547 (20%) 113/546 (21%) 99/544 (18%)
Number of days reduced usual activity 3.8 (6.5), N 5 548 3.6 (5.9), N 5 546 3.4 (5.3), N 5 545
Physical functioning (RMDQ) 12.8 (5.6), N 5 543 13.2 (5.4), N 5 532 13.3 (5.5), N 5 531
Feelings of depression in last week 3.2 (2.9), N 5 547 3.1 (2.9), N 5 546 3.1 (2.9), N 5 546
Perceived risk of persistent pain 4.6 (2.8), N 5 548 4.6 (2.8), N 5 546 4.4 (2.8), N 5 545
Back pain episode compensable 31/546 (6%) 44/543 (8%) 43/546 (8%)
Pain intensity (NRS) 6.3 (1.9), N 5 550 6.3 (2.0), N 5 545 6.2 (1.8), N 5 546
Global rating of change 0.0 (2.1), N 5 548 0.1 (2.2), N 5 545 0.1 (2.1), N 5 546
Poor sleep quality 273/549 (50%) 272/545 (50%) 272/546 (50%)
Function (Nominated Activity) 3.5 (1.7), N 5 547 3.6 (1.9), N 5 544 3.7 (1.9), N 5 545
Quality of lifedphysical (SF-12) 42.7 (9.1), N 5 537 41.8 (9.7), N 5 543 42.1 (9.2), N 5 538
Quality of lifedmental (SF-12) 44.1 (7.7), N 5 537 44.6 (7.7), N 5 543 44.4 (7.9), N 5 538
Credibility score (CEQ) 19.0 (4.9), N 5 544 18.5 (5.2), N 5 542 19.4 (4.9), N 5 540
Expectation score (CEQ) 19.7 (5.3), N 5 544 19.6 (5.1), N 5 542 20.2 (5.1), N 5 542
Abbreviations: AUD, Australian dollars; CEQ, credibility/expectancy questionnaire; LBP, low back pain; NRS, numerical rating scale; PSQI,
Pittsburgh Sleep Quality Index; RMDQ, Roland Morris Disability Questionnaire; SF-12, 12-item Short Form Survey.
Data are mean (SD) or n/N (%).
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group). All treatment coefficients indicated no effect of
treatment on pain intensity during 28 days of follow-up
(Table 3A); no estimates exhibited between-group differ-
ences (even without correction for multiple testing).
Furthermore, CIs for the coefficients were between 0.1
and þ0.1 and did not include a clinically worthwhile effect
of treatment with paracetamol (taken regularly or as-
needed) on pain intensity when compared with placebo.
The estimates for treatment coefficients for physical
functioning and HRQoL, odds ratios for poor sleep quality,
and hazard ratios for recovery from LBP indicated no effect
of treatment without correction for multiple testing
(Table 3B). Furthermore, clinically worthwhile differences
were not included in the CIs for these estimates.
A graphical representation of the effects of treatment
during follow-up is shown in Figure 1; graphs wereobtained from uncorrected regression models containing
only treatment and time as covariates. The lines for
different treatment groups are very close in all graphs
(and sometimes nearly indistinguishable), emphasizing no
difference in effect between paracetamol and placebo. Pain
intensity (Figure 1A) steadily declines over time in all treat-
ment groups. For physical functioning (Fig. 1B), a sharp
decline can be observed during the first 4 weeks of
follow-up, followed by a stable phase until 12 weeks of
follow-up. Although the mental component of HRQoL re-
mained constant during the trial (Fig. 1C), the physical
component of HRQoL steadily increased during 12 weeks
of follow-up, indicating an improvement of HRQoL over
time (Fig. 1D). The probability of poor sleep quality
steadily declined during 12 weeks of follow-up.
Figure 1F illustrates the recovery curves as well as me-
dian recovery times for the three treatment groups;
Table 3. Coefficients for effect of treatment on log average pain intensity (primary outcome) during 28 days of follow-up and for secondary outcomes
during 12 wk of follow-up
A. Primary outcome
Regular paracetamol vs.
placebo, b (95% CI)
Paracetamol as needed vs.
placebo, b (95% CI)
Regular paracetamol vs.
paracetamol as-needed, b (95% CI)
Pain intensity (NRS, scale
range 0e10)
0.00 (0.02, 0.01); P 5 0.85 0.00 (0.02, 0.01); P 5 0.92 0.00 (0.02, 0.01); P 5 0.92
B. Secondary outcomes Regular paracetamol vs.
placebo, b (95% CI)
Paracetamol as-needed vs.
Placebo, b (95% CI)
Regular paracetamol vs. paracetamol
as-needed, b (95% CI)
Physical functioning (RMDQ,
scale range 0e24)
0.06 (0.13, 0.01); P 5 0.11 0.03 (0.10, 0.04); P 5 0.39 0.03 (0.09, 0.04); P 5 0.46
HRQoLdmental (SF-12) 0.13 (0.72, 0.47); P 5 0.67 0.17 (0.42, 0.76); P 5 0.58 0.30 (0.89, 0.30); P 5 0.33
HRQoLdphysical (SF-12) 0.00 (0.77, 0.77); P 5 1.00 0.14 (0.91, 0.62); P 5 0.71 0.14 (0.62, 0.91); P 5 0.71
Sleep quality (PSQI) OR 1.03 (0.90, 1.19); P 5 0.62 OR 1.04 (0.91, 1.19); P 5 0.59 OR 1.00 (0.87, 1.14); P 5 0.97
Time until first recovery HR 1.02 (0.88, 1.18); P 5 0.82 HR 1.02 (0.88, 1.19); P 5 0.76 HR 0.99 (0.86, 1.15); P 5 0.93
Abbreviations: HR, hazard ratio; NRS, numerical rating scale; OR, odds ratio; PSQI, Pittsburgh Sleep Quality Index; RMDQ, Roland Morris
Disability Questionnaire; SF-12: Short Form 12.
All numbers rounded to two decimal places. All models were corrected for sex, age, employment status, income, use of medication for other
disorders, health insurance status and back pain compensability, days since onset of pain, number of previous episodes, radiating pain beyond
the knee, number of days reduced activity, feelings of depression, perceived risk of persistent pain, pain intensity, global rating of symptom change,
physical functioning, patient specific function, sleep quality, credibility, expectations and physical and mental health-related quality of life (all
measured at baseline).
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formation for 1,601 participants; for 13 additional patients
with all pain diary data missing, a recovery date was avail-
able, yielding a total of 1,614 patients for the analysis (542
in the regular paracetamol group, 535 in the paracetamol
as-needed group, and 537 in the placebo group). Of 1,614
participants, 1,186 (73%) had recovered from LBP after
28 days of follow-up. Median recovery times were 13 days
(95% CI: 11e14 days), 14 days (95% CI: 13e15 days), and
12 days (95% CI: 10e14 days) in the regular paracetamol,
paracetamol as-needed, and placebo groups, respectively.
There was no difference between the three recovery curves
(log-rank P 5 0.7). In Supplementary Figure 2, the results
of the analysis for the sensitivity to missing data were pre-
sented. The results did not substantially change in the sensi-
tivity analyses when compared with the available data
analysis.
In Table 4, results for the subgroups for severe baseline
LBP intensity (defined as NRS  7) and severe baseline
impairment of physical functioning (defined as
RMDQ  16) are displayed. The results did not substan-
tially change in the subgroups when compared with the
main analysis. Figure 2 shows the recovery curves for these
subgroups. In the severe baseline LBP intensity subgroup,
547 of 776 participants (70%) had recovered from LBP af-
ter 28 days of follow-up. Median recovery times were
14 days (95% CI: 13e19 days), 16 days (95% CI:
14e18 days), and 13 days (95% CI: 11e17 days) in the
regular paracetamol, paracetamol as-needed, and placebo
groups, respectively. There was no difference between the
three recovery curves (log-rank P 5 0.8). In the severe
baseline impairment of physical functioning subgroup,
420 of 592 participants (71%) had recovered from LBPafter 28 days of follow-up. Median recovery times were
16 days (95% CI: 13e19 days), 16 days (95% CI:
14e19 days), and 14 days (95% CI: 11e21 days) in the
regular paracetamol, paracetamol as-needed, and placebo
groups, respectively. There was no significant difference
between the three recovery curves (log-rank P 5 0.9).4. Discussion
We performed an inferential reproduction analysis of
data collected in the PACE trial, using the predefined and
published analysis plan from the PACE Plus trial; key dif-
ferences between the original analysis and the current rean-
alysis include a different primary outcome and different
analysis methods, follow-up time points, presented out-
comes, and subgroup analyses [8,16]. In our reanalysis of
the PACE-trial data, the treatment of patients with acute
LBP with paracetamol (taken regularly or as-needed) had
no effect on pain intensity, physical functioning, HRQoL,
and time until recovery from LBP when compared with pla-
cebo; our study thus confirmed the original results of the
PACE trial [8].
A strength of this study is the fact that the predefined
and published analysis plan from a discontinued replication
trial of PACE was used [16]. Furthermore, Poisson mixed
models have been demonstrated to be more appropriate
for the analysis of zero-inflated ordinal data such as data
obtained from the NRS and the RMDQ than linear mixed
models [27,28]. A weakness of this study is the fact that
the published analysis plan could not be completely used
as intended because of differences between the PACE trial
and the PACE Plus trial [16]. Although the PACE trial had
Fig. 1. Effects of treatment on core outcomes of LBP (pain intensity (A), physical functioning (B) and HRQoL (C and D), sleep quality (E), and time
until first recovery from LBP (F). Graphs obtained from uncorrected regression models containing only treatment and time as covariates. Y-axis was
truncated for plots B, C, D, E, and F to improve visibility of results. Red line indicates placebo group, green line indicates paracetamol as-needed
group, blue line indicates regular paracetamol group. HRQoL, health-related quality of life; LBP, low back pain; NRS, numerical rating scale; PSQI,
Pittsburgh Sleep Quality Index; RMDQ, Roland Morris Disability Questionnaire; SF12, Short Form 12.
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as-needed, and placebo), the PACE Plus trial had four treat-
ment groups (regular paracetamol, regular diclofenac, pla-
cebo, and advice-only). Furthermore, as mentioned in the
‘‘Methods’’ section, not all outcome domains were the
same between both trials, meaning we could only use part
of the analysis plan as well as part of the available data
collected in the PACE trial; however, despite some differ-
ences, the core outcome domains and instruments for
LBP were included in the reproduction analysis [19,22].Second, authors deviated from the original protocol using
Poisson mixed effect models rather than the predefined
linear mixed effects models, but the nature of the data obli-
gated this change. Finally, this reanalysis of the PACE trial
focused on the ITT analysis, which remains the least biased
method and, therefore, the most relevant analysis for clin-
ical practice [34]; adherence to medication was not taken
into account. However, it has been demonstrated that
compliance patterns are unlikely to change the conclusions
about the efficacy of paracetamol for acute LBP [35].
Table 4. Coefficients for subgroups for effect of treatment on average pain intensity (primary outcome) and time until first recovery during 28 days of
follow-up and on average physical function during 12 wk of follow-up
Subgroup 1: severe baseline LBP
intensity (defined as NRS ‡ 7)
Regular paracetamol vs.
placebo, b (95% CI)
Paracetamol as-needed vs.
placebo, b (95% CI)
Regular paracetamol vs. paracetamol
as-needed, b (95% CI)
Pain intensity (NRS, scale
range 0e10)
0.02 (0.09, 0.05); P 5 0.49 0.00 (0.07, 0.07); P 5 0.96 0.02 (0.09, 0.05); P 5 0.53
Physical functioning (RMDQ,
scale range 0e24)
0.01 (0.11, 0.08); P 5 0.80 0.01 (0.10, 0.09); P 5 0.88 0.01 (0.10, 0.09); P 5 0.91
Time until recovery HR 1.04 (0.83, 1.30) P 5 0.74 HR 1.09 (0.88, 1.36) P 5 0.44 HR 0.95 (0.77, 1.19); P 5 0.67
Subgroup 2: severe baseline
impairment of physical
functioning (defined as
RMDQ  16)
Regular paracetamol vs.
placebo, b (95% CI)
Paracetamol as-needed vs.
Placebo, b (95% CI)
Regular paracetamol vs. paracetamol
as-needed, b (95% CI)
Pain intensity (NRS, scale
range 0e10)
0.00 (0.10, 0.10); P 5 0.99 0.03 (0.07, 0.12); P 5 0.58 0.03 (0.12, 0.07); P 5 0.59
Physical functioning (RMDQ,
scale range 0e24)
0.02 (0.06, 0.11); P 5 0.56 0.03 (0.11, 0.05); P 5 0.50 0.05 (0.03, 0.13); P 5 0.20
Time until recovery HR 1.02 (0.79, 1.30); P 5 0.89 HR 1.08 (0.84, 1.38); P 5 0.53 HR 0.94 (0.73, 1.21); P 5 0.64
Abbreviations: HR, hazard ratio; LBP, low back pain; NRS, numerical rating scale; RMDQ, Roland Morris Disability Questionnaire.
Subgroups were severe LBP intensity (defined as NRS  7) and severe impairment of physical functioning (defined as RMDQ  16) at baseline.
All numbers rounded to two decimal places. All models were corrected for sex, age, employment status, income, use of medication for other dis-
orders, health insurance status and back pain compensability, days since onset of pain, number of previous episodes, radiating pain beyond the
knee, number of days reduced activity, feelings of depression, perceived risk of persistent pain, pain intensity, global rating of symptom change,
physical functioning, patient-specific function, sleep quality, credibility, expectations and physical and mental health-related quality of life (all
measured at baseline).
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of pain diary data up to 28 days of follow-up (upon which
the recovery analysis was based), the authors decided not to
use any data gathered in the PACE trial after 28 days of
follow-up, as this would not have been available in theFig. 2. Survival curves for time until first recovery in subgroups. Subgroups
severe baseline physical functioning (defined as RMDQ  16).PACE Plus study; furthermore, the analysis for this repro-
duction analysis was conducted on available data with
sensitivity analyses for missing data, whereas in the orig-
inal report, data were imputed to obtain complete groups
for the recovery analysis. A consequence of these decisionswere (A) severe baseline LBP intensity (defined as NRS  7) and (B)
Box 1 Comments on this inferential reproduction
analysis of PACE by the original authors
The inferential reproduction analysis of the PACE
study, conducted by an independent group based on
a predefined statistical analysis plan of a similar study
(PACE Plus), agrees with the conclusion from the
original PACE analysisdthat paracetamol has no ef-
fects on pain or other core outcomes compared with
placebo in patients with acute LBP.
This study joins other secondary analyses of the
PACE study showing the lack of benefits of paracet-
amol: we have also found that paracetamol did not
improve pain intensity even in patients who complied
with the regular treatment regimen (article to be pub-
lished in 2019), and taking paracetamol did not
confer any economic benefits in patients with acute
LBP [1]. However, we await the most important
and currently missing step in definitively confirming
the results of PACEda replication of the PACE
study.
We would encourage other trialists to make their
datasets available to allow reanalysis of the data by
independent groups.
53M. Schreijenberg et al. / Journal of Clinical Epidemiology 121 (2020) 45e54is that patients who recovered after 28 days of follow-up
were considered censored in the current version of the re-
covery analysis; this may be an explanation for the differ-
ence in median recovery times (13, 12, and 14 days in
the regular paracetamol, paracetamol as-needed, and pla-
cebo groups, respectively, vs. 17, 16 and 17 days as re-
ported in the original report).
This reanalysis of the PACE data yielded no substantially
different results, and therefore, the interpretation of the
PACE trial remains the same: paracetamol (taken regularly
or as needed) did not improve outcomes of LBP when
compared with placebo. Thus, this study supports the notion
that paracetamol has a limited role in the management of
acute LBP in general practice. Furthermore, this reanalysis
confirms that prognosis of acute LBP is favorable, and that
natural course or regression to the mean (Fig. 1), rather than
pharmacological treatment, is important factors influencing
core outcomes’ trajectory in patients with acute LBP.
The clinical implementation of the results of the PACE
trial, of course, depends on the acceptability of taking no
pain medication, but receiving only reassurance and advice
to stay active for patients with acute nonspecific LBP. In
practice, this may be feasible if clinicians can invest more
time in explaining to patients that the effects of pharmaco-
logical interventions for LBP are expected to be limited,
although there is a risk of adverse events. Unfortunately, in
many countries, GPs have very limited time for each patient,
and this may be a barrier to successful implementation. Analternative for clinicians could be to recommend nonphar-
macological interventions to patients with LBP (e.g., super-
ficial heat, acupuncture, and spinal manipulative therapy or
massage) [4]; such interventions may not have larger effects
than pharmacological options, but they are associated with a
lower risk of adverse events. Although method reproduc-
ibility and inferential reproducibility have now been ad-
dressed for the PACE trial, results reproducibility (also
called replication) has not [8,10,11]. However, a recent study
by Friedman et al compared the combination of the NSAID
ibuprofen and paracetamol with the combination of
ibuprofen and placebo for patients with acute LBP reporting
to two American emergency departments [36]. Although the
research question, setting, patient population, and follow-up
time were different from the PACE trial, the conclusions
regarding the efficacy of paracetamol were the same as those
made in the original PACE study. Rather than reproducing
the results of PACE in a new RCT, the authors would recom-
mend conducting a meta-analysis of this new study and the
PACE trial to more conclusively establish the efficacy of
paracetamol for acute LBP.5. Conclusions
This inferential reproduction analysis indicates that the
treatment of patients with acute LBP with paracetamol
(taken regularly or as-needed) has no effect on core out-
comes of LBP when compared with placebo and thus con-
firms the original results of the PACE trial [8]. This means
the original conclusions of the PACE trial are inferentially
reproducible, even when using a different approach to the
statistical analysis.CRediT authorship contribution statement
Marco Schreijenberg: Software, Formal analysis,
Writing - original draft. Alessandro Chiarotto: Software,
Writing - review & editing. Katya A.L. Mauff: Software,
Formal analysis, Writing - review & editing. Chung-Wei
Christine Lin: Conceptualization, Investigation, Formal
analysis, Writing - original draft. Christopher G. Maher:
Conceptualization, Investigation, Formal analysis, Writing
- original draft. Bart W. Koes: Software, Writing - review
& editing.Acknowledgments
The authors thank the participants of this research, the
clinicians involved in participant recruitment, and the
research support staff involved in site monitoring, data
collection, data management, and data analysis.
Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jclinepi.2020.01.010.
54 M. Schreijenberg et al. / Journal of Clinical Epidemiology 121 (2020) 45e54References
[1] Lin CC, Li Q, Williams CM, Maher CG, Day RO, Hancock MJ, et al.
The economic burden of guideline-recommended first line care for
acute low back pain. Eur Spine J 2018;27(1):109e16.
[2] Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and
sciatica: summary of NICE guidance. BMJ 2017;356:i6748.
[3] Chenot JF, Greitemann B, Kladny B, Petzke F, Pfingsten M,
Schorr SG. Non-specific low back pain. Dtsch Arztebl Int 2017;
114(51e52):883e90.
[4] Qaseem A, Wilt TJ, McLean RM, Forciea MA. Clinical Guidelines
Committee of the American College of P. Noninvasive treatments
for acute, subacute, and chronic low back pain: a clinical practice
guideline from the American College of physicians. Ann Intern
Med 2017;166:514e30.
[5] Van Wambeke P, Desomer A, Ailliet L, ABerquin A, Demoulin C,
Depreitere B, et al. Low back pain and radicular pain: assessment and
management. Brussels: Belgian Health Care Knowledge Centre; 2017.
[6] Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CC, Chenot JF,
et al. Clinical practice guidelines for the management of non-specific
low back pain in primary care: an updated overview. Eur Spine J
2018;27(11):2791e803.
[7] Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel
Shaheed C, Maher CG. Paracetamol for low back pain. Cochrane
Database Syst Rev 2016CD012230.
[8] Williams CM, Maher CG, Latimer J, McLachlan AJ, Hancock MJ,
Day RO, et al. Efficacy of paracetamol for acute low-back pain: a
double-blind, randomised controlled trial. Lancet 2014;384:1586e96.
[9] Schreijenberg M, Koes BW, Lin CC. Guideline recommendations on
the pharmacological management of non-specific low back pain in
primary care - is there a need to change? Expert Rev Clin Pharmacol
2019;12:145e57.
[10] Goodman SN, Fanelli D, Ioannidis JP. What does research reproduc-
ibility mean? Sci Transl Med 2016;8(341):341ps12.
[11] Plesser HE. Reproducibility vs. Replicability: a brief history of a
confused terminology. Front Neuroinform 2017;11:76.
[12] Lee H, Lamb SE, Bagg MK, Toomey E, Cashin AG, Moseley GL.
Reproducible and replicable pain research: a critical review. Pain
2018;159(9):1683e9.
[13] Patil P, Peng RD, Leek JT. A statistical definition for reproducibility
and replicability. BioRxiV 2017.
[14] Prasad V, Gall V, Cifu A. The frequency of medical reversal. Arch
Intern Med 2011;171:1675e6.
[15] Niven DJ, McCormick TJ, Straus SE, Hemmelgarn BR, Jeffs L,
Barnes TRM, et al. Reproducibility of clinical research in critical
care: a scoping review. BMC Med 2018;16(1):26.
[16] Schreijenberg M, Luijsterburg PA, Van Trier YD, Rizopoulos D,
Koopmanschap MA, Voogt L, et al. Efficacy of paracetamol, diclofe-
nac and advice for acute low back pain in general practice: design of
a randomized controlled trial (PACE Plus). BMC Musculoskelet Dis-
ord 2017;18(1):56.
[17] Schreijenberg M, Luijsterburg PAJ, Van Trier YDM, Rizopoulos D,
Koopmanschap MA, Voogt L, et al. Discontinuation of the PACE
Plus trial: problems in patient recruitment in general practice. BMC
Musculoskelet Disord 2018;19(1):146.
[18] Froud R, Patterson S, Eldridge S, Seale C, Pincus T, Rajendran D,
et al. A systematic review and meta-synthesis of the impact of low
back pain on people’s lives. BMC Musculoskelet Disord 2014;15:50.[19] Chiarotto A, Deyo RA, Terwee CB, Boers M, Buchbinder R,
Corbin TP, et al. Core outcome domains for clinical trials in non-
specific low back pain. Eur Spine J 2015;24(6):1127e42.
[20] Williams CM, Latimer J, Maher CG, McLachlan AJ, Cooper CW,
Hancock MJ, et al. PACE–the first placebo controlled trial of paracet-
amol for acute low back pain: design of a randomised controlled trial.
BMC Musculoskelet Disord 2010;11:169.
[21] Williams CM, Maher CG, Latimer J, McLachlan AJ, Hancock MJ,
Day RO, et al. PACE–the first placebo controlled trial of paracetamol
for acute low back pain: statistical analysis plan. Trials 2013;14:248.
[22] Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP,
Costa LOP, et al. Core outcome measurement instruments for clinical
trials in nonspecific low back pain. Pain 2018;159(3):481e95.
[23] Roland M, Morris R. A study of the natural history of back pain. Part
I: development of a reliable and sensitive measure of disability in
low-back pain. Spine 1983;8(2):141e4.
[24] Brazier JE, Roberts J. The estimation of a preference-based measure
of health from the SF-12. Med Care 2004;42:851e9.
[25] Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The
Pittsburgh Sleep Quality Index: a new instrument for psychiatric
practice and research. Psychiatry Res 1989;28:193e213.
[26] R Core Team. R. A language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical Computing;
2018.
[27] Goulet J, Buta E, Carroll C, Brandt C. Statistical methods for the
analysis of NRS pain data. J Pain 2015;16(4):S7.
[28] Goulet JL, Buta E, Bathulapalli H, Gueorguieva R, Brandt CA. Sta-
tistical models for the analysis of zero-inflated pain intensity numeric
rating scale data. J Pain 2017;18:340e8.
[29] Rizopoulos D. GLMMadaptive: generalized linear mixed models us-
ing adaptive Gaussian quadrature. R package version 0.5-1. 2019.
Available at https://CRAN.R-project.org/package=GLMMadaptive.
Accessed August 13, 2019.
[30] Ferreira ML, Ferreira PH, Herbert RD, Latimer J. People with low
back pain typically need to feel ’much better’ to consider intervention
worthwhile: an observational study. Aust J Physiother 2009;55(2):
123e7.
[31] Ferreira ML, Herbert RD, Ferreira PH, Latimer J, Ostelo RW,
Grotle M, et al. The smallest worthwhile effect of nonsteroidal
anti-inflammatory drugs and physiotherapy for chronic low back
pain: a benefit-harm trade-off study. J Clin Epidemiol 2013;66:
1397e404.
[32] Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-
effects models using lme4. J Stat Softw 2015;67(1):1e48.
[33] Therneau T. A package for survival analysis in S. version 2.38. 2015.
Available at https://CRAN.R-project.org/package=survival. Accessed
August 13, 2019.
[34] Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res
2011;2(3):109e12.
[35] Schreijenberg M, Lin CC, McLachlan AJ, Williams CM, Kamper SJ,
Koes BW, et al. Paracetamol is ineffective for acute low back pain
even for patients who comply with treatment: complier average
causal effect analysis of a randomized controlled trial. Pain 2019;
160(12):2848e54.
[36] Friedman BW, Irizarry E, Chertoff A, Feliciano C, Solorzano C,
Zias E, et al. Ibuprofen þ acetaminophen versus ibuprofen alone
for acute low back pain. An ED-based randomized study. Acad
Emerg Med 2019.
